Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN1012 in Pre-malignant Oral Dysplasia
NCT07620496Phase 1Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2031
01
Overview
Phase 1, open-label trial of CAN1012 in Oral epithelial dysplasia (OED) (4 arms). Primary endpoint: Safety and Tolerability. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CAN1012
03
Conditions
Oral epithelial dysplasia (OED)
Beyond the preview
Go deeper on NCT07620496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620496.